Investor FAQs

We have not changed our IR/PR service provider, Optimum Strategic Healthcare are appointed and will continue to provide IR/PR services.  Brighter IR is the new provider we use to feed share price information to our website and to provide the news alert service which enables users who are registered with their service to receive alerts when regulatory news is released to the Futura website.

With the introduction of GDPR, Brighter IR requires your permission to use your personal information to contact you and this is done via their registration.  Please note that once registered, you will begin to receive news alerts via email.  You do not need to log into the Brighter IR portal to access the press releases, they are available on our website through the automated feed.  The Brighter IR portal is to allow you to amend or delete the permissions you have given to them to access your personal information and to contact you via the alert service.

DermaSys^® is a proprietary transdermal technology platform with very strong IP offering a high level of product differentiation compared to existing marketed treatments. Each new unique formulation offers the opportunity for additional patent applications and potential patent protection. 

MED3000 is a topical gel applied directly to the head (glans) of the penis for the treatment of ED.

MED3000 works through a unique evaporative mode of action. MED3000’s combination of volatile components creates a novel cooling and recovery warming  action that stimulates nerve sensors in the highly innervated glans penis, rapidly leading to smooth muscle relaxation, tumescence and erection.

Futura aims to create a network of licensing and distribution partners with strength in brand building, pharmaceutical credibility and regional infrastructure and marketing expertise for long-term distribution of MED3000 across the globe. We continue to target initial launches later in 2022, although exact markets have not yet been agreed with distribution partners. Further launches are expected in in 2023.

In April 2021 the Company announced that it received its MDR EU Quality Management Certificate for the placing on the market of a Class 2B medical device known as MED3000 ("CE mark approval"). Futura's breakthrough, fast acting topical gel formulation MED3000, is the first clinically proven, pan-European topical treatment for adult men with ED available without a doctor's prescription ("OTC").

The CE mark approval of MED3000 from the EU Notified Body1 paves the way for approval in many countries around the world, including in the Middle East, Africa and the Far East regions which allow "fast-track" review based on recognition of the EU CE mark. Due to post-Brexit arrangements, the EU CE mark can be used to market the product in Great Britain until 30 June 2023 by which time a specific UKCA mark has to be obtained. This will be a streamlined process since it is understood the UK application can bridge to the EU approval.

Futura has retained specialist corporate advisers to assist the company in the appointment of world-wide distribution partners. All distribution and marketing aspects of MED3000 including launch will be handled by them. Futura's breakthrough, topical gel formulation MED3000 will become the first pan-European topical treatment for erectile dysfunction ("ED") available without the need of a doctor's prescription.

We are currently targeting initial launches in Europe in H1 2023.

Note

^¹Notified Bodies are organizations designated by EU countries to oversee the approval of medical devices within the EU and the UK.

MED3000 is currently not available for purchase.

As previously announced, following a number of meetings with the US Food and Drug Administration (FDA) the FDA agreed that an application may be made for MED3000 as a medical device for ED treatment, with a De Novo classification. A number of pre-submissions meeting with the FDA took place to define and confirm the detail of the work required for OTC classification in the USA for MED3000.

Data from a confirmatory clinical study, FM71, announced in September 2022, alongside additional data from previously announced FM57, supports the US regulatory submission for MED3000 with an application for OTC designation. The dossier is on track for submission at the end of September 2022.

US marketing authorisation of MED3000 by the FDA remains on course for Q1 2023.

We don’t anticipate needing to complete any further trials to obtain FDA granting marketing authorisation 

The approval of MED3000 from the EU Notified Body (as announced on Friday 30 April) paves the way for rapid approval in many countries around the world, including in the Middle East, Africa, the Far East and Latin American regions which allow “fast-track” review based on recognition of the EU CE mark. Depending on the country these approvals are likely to take between 6 and 12 months from the time of submission.

In 2021 Futura signed three commercial deals:

March 2021: Co-High Investment Management to commercialise MED3000 in China and South East Asia.

August 2021:  m8 Pharmaceuticals to commercialise MED3000 in Brazil and Mexico.

September 2021:  Labatec Pharma to commercialise MED30 00 in the Gulf and Middle East Region.

In 2022, Futura entered into the following commercial deals:

March 2022: A. Menarini Korea Limited for the exclusive rights to MED3000 in South Korea.

May 2022: Cooper Consumer Health to commercialise MED3000 throughout the European Economic Area, United Kingdom and Switzerland.

All distribution will be handled by our appointed distribution partners and retailers. MED3000 addresses the significant and specific medical needs of men who suffer from erectile dysfunction and its use, where approved to be a treatment without the need for a doctor’s prescription, will require careful consideration by the patient in terms of self-diagnosis and use according to product label information.

EROXON™ is a gel that is a clinically proven treatment for erectile dysfunction and helps give adult men an erection within 10 minutes.  Eroxon™ is also available without the need of a doctor’s prescription.

Futura has granted Cooper Consumer Health SAS (“Cooper”) exclusive marketing and distribution rights for Eroxon™ throughout the European Economic Area including the United Kingdom and Switzerland.  All product or sales enquiries will be handled directly by Cooper including professional samples that may be available to healthcare practitioners.

Contact details can be found at www.cooperconsumerhealth.eu/

At this time we have not tested the product in patients who have undergone radical prostatectomy although the product has been shown to be effective in mild, moderate and severe ED of mixed causes.

If you have a medical condition you may need to speak to a doctor to discuss your condition to see if the product is suitable for you to use.

MED3000 will come with a leaflet part of which will cover warnings and precautions and recommend users have a check-up with their doctor as soon as possible within the first 6 months of using MED3000 to ensure that any erection problems are not caused by another serious health condition.

We anticipate a shelf life of 3 years.

The final price has yet to determine however market research supports a single dose price in the region of £5.00

We have not conducted studies on MED3000 in combination with PDE5i’s and it is not included on our proposed label. It is likely that a post-approval study will be needed to demonstrate synergy. We do not anticipate any safety issues in combining the two treatments   Regulatory status in other geographies, especially where there are commercialisation agreements in place e.g. China, LatAm, Gulf States

Tadalafil was chosen as a control product at the original suggestion of FDA. We agreed with the choice as it represents a widely used marketed product in the USA. After discussion with FDA, they agreed that we could use the lowest effective and approved dose in the USA (5mg). As indicated above, the purpose of including and assessing relative efficacy and safety is to help FDA determine the benefit risk ratio for MED3000 against a marketed control. It is not a pre-requisite for success in the study that we match the efficacy of tadalafil.

Unlike MED3000, oral tadalafil failed to meet the criteria agreed with FDA to demonstrate onset of action within 10 minutes. Oral tablets typically take 30-60 minutes to work.

In August 2022, Futura announced positive results from the confirmatory Phase 3 clinical study, “FM71” for MED3000, for the treatment of erectile dysfunction.

• FDA agreed co-primary endpoints met at 24 weeks, demonstrating a statistically significant improvement in erectile function compared to baseline, as well as achieving a clinically important improvement in erectile function at 24 weeks
• Secondary endpoint met demonstrating a 10-minute onset of action, which was demonstrably faster than the well-known prescription oral medication used in the study
• Exploratory endpoints demonstrated MED3000 achieved clinically important improvements in erectile function and was clinically effective in mild, moderate and severe ED sufferers
• Safety and tolerability data were also highly positive, with no serious adverse events recorded in any patients on MED3000 and overall, with a highly favourable side-effect profile

MED3000 presents an effective clinically proven treatment for erectile dysfunction (“ED”) with a rapid speed of onset and a favourable benefit versus risk profile ideally suited for Over the Counter (“OTC”) classification1

Futura on track to file dossier with the US FDA by the end of September, targeting marketing authorisation by the FDA of MED3000 in Q1 2023 as the first major ED treatment available OTC throughout the USA.

Further information can be found in the FM71 study results press release here, and the FM71 study results webcast here

“Clinically proven gel to treat erectile dysfunction” and “Helps you get an erection within 10 minutes” are the approved EU and UK claims. These claims are subject to ratification by FDA.

In February 2019, the UK Medicines and Healthcare products Regulatory Agency (MHRA) responded to Thornton & Ross’s marketing authorisation application filed in July 2018, raising a number of questions requiring additional laboratory work specifically around the permeation characteristics of TPR100 to be conducted.  The additional lab work has been completed indicating that absorption of TPR100 is significantly superior to the market leader. These results were discussed with MHRA in a Scientific Advice meeting and it was determined that as there was non-equivalency a clinical study was required. MHRA suggested that the clinical study could be used to support superiority claims for the formulation. Futura are determining how this study could be funded and used to support the product in markets around the world including the US where Voltaren (GSK) has recently achieved OTC designation.

Our transdermal technology DermaSys^® is tailored for each product to suit the specific therapeutic indication and desired speed of onset and duration of action offering improvements over existing products creating novel indications with compelling commercial potential. This means that our products are highly differentiated in their markets whilst avoiding the risks normally associated with the development of new molecules.

The rapid skin permeation rate offered by our transdermal delivery system, DermaSys^®, is ideally suited for targeted topical pain relief. Rapid, targeted and effective skin permeation offers potential benefits in pain management including: improved onset of action, duration and degree of pain relief.

TPR100 does not require a combination of volatile solvent components to stimulate nerve sensors.  It is designed to provide a sustained mode of action suitable for the treatment of pain and is formulated with this objective in mind.

TPR100's current patent protection runs until February 2028 in the USA and Europe.

CBDerma Technology is a company that has been established with backers that have experience in plant derived products. Futura announced a joint venture collaboration with CBDerma Technology Limited in September 2019 to explore the application of Futura’s advanced proprietary transdermal technology, DermaSys^® for the delivery of cannabidiol.

The cosmetic market is already significant with the UK, we understand, over £300 million.  As a topically applied Pharmaceutical the potential is huge but under-explored so far, with currently very little credible scientific research conducted on topical formulations.

DermaSys^® provides rapid and targeted local delivery of active pharmaceutical ingredients (API) at therapeutic levels and Generally Recognized As Safe (GRAS) pharmaceutical excipients onto and through the skin to the required site of action with a high level of safety. It is a versatile and bespoke technology that can be tailored to suit the specific active compound being used and the therapeutic indication. Each product is formulated to maximise its benefits for patients and consumers and can be developed for the prescription and consumer healthcare markets as appropriate.

Our transdermal technology DermaSys^® is tailored for each product to suit the specific therapeutic indication and desired speed of onset and duration of action offering improvements over existing products creating novel indications with compelling commercial potential. This means that our products are highly differentiated in their markets whilst avoiding the risks normally associated with the development of new molecules.

CBD100 comprises a unique combination of penetration enhancers components and a diffusion enhancer. It is designed to provide highly efficient penetration of cannabidiol into and through the skin with a stability expected to ensure potency is retained during shelf-life.

A patent application was filed in the UK in August 2020.

We would expect to receive an initial search report on the ‘patentability’ of such application within six months.  This will provide details of other patents or application already in existence which may affect the novelty and inventiveness of any new application.  This may result in some amendment to the patent application ahead of a PCT application next July.

We are aiming for CBD100 to be highly differentiated from existing, largely un-regulated, low-tech products in the fast growing cannabidiol market on the basis of quality, stability and efficient delivery to the skin for a number of applications and indications expected to range from cosmeceutical through to pharmaceutical dermal and pain relief treatments. We have now started to explore commercialisation options for CBD100 with CBDerma as stability work continues in parallel.  These options will also be influenced by the regulatory landscape around Cannabis which continues to evolve in the EU and USA.

Unfortunately, under the current regulations, Futura Medical are not able to provide samples.

The maximum payment made by the Company was £4,000.

An initial UK patent was filed in December 2019 around MED3000’s clinically significant and novel findings shown in FM57 followed by further supplementary UK filings to establish a priority date prior to a Patent Cooperation Treaty (“PCT”) and certain non-PCT patent applications in late 2020.

The PCT currently has 153 contracting countries where the Company can seek patent protection claiming priority from an original application such as the UK. 

An application to the European Patent Office was also made in August 2021 for examination and further national applications in line with normal PCT filing procedure will be made in Q2 2022 in those countries considered necessary to protect the commercial interests of MED3000. If national applications are successful this will provide patent protection until 2040.

Futura's unique patented technology DermaSys^® is designed to deliver clinically proven effective medical treatments via the skin.

DermaSys^® is a versatile and bespoke technology. Each product gel is uniquely formulated using the DermaSys^® platform with permeation and penetration enhancer components formulations tailored for each product to suit the specific therapeutic indication and desired speed of onset and duration of action. Such targeted delivery offers an optimised profile in terms of dose, onset time and duration of effect as well as an improved safety profile reducing the risk of side effects. Each product is formulated to maximise its benefits for patients and consumers. Each new unique formulation offers the opportunity for additional patent applications and potential patent protection.